Background: Lenakap clinical trial (ANRS 154) is a single-arm, multicenter, open label, phase II trial, evaluating the efficacy and safety of lenalidomide in Kaposi’s sarcoma (KS) associated with HIV infection (AIDS-KS) despite an effective antiretroviral (ARV) therapy (NCT01282047). KS is a human herpesvirus 8 (HHV-8)-associated disease. It is known that cytokines are required for the development of KS, but so far no biomarker has been identified. We investigated if the CXCL12/CXCR4-CXCR7 pathway, a trio of chemokine and G protein-coupled receptors known to be involved in many cancers, could be a candidate.
Methods: The expression of CXCL12, CXCR4, CXCR7 and different markers, i.e. LANA (HHV-8 latency-associated nuclear antigen), Ki67 (cell proliferation), TUNEL (apoptosis) and VEGF (angiogenesis), were analyzed in AIDS-KS cutaneous biopsies (CBs) (n=16) by immuno-histochemistry. Twenty angiomas and 21 classic KS CBs were used as negative and positive controls respectively. Protein expression was quantified using the Visilog software. Mann-Withney test and Pearson correlation were estimated using Prism 5 software. P values <0.05 were considered as statistically significant.
Results: Overall 379 staining of CXCL12, CXCR4, CXCR7, Ki67, LANA, TUNEL and VEGF were performed. Levels of CXCL12, CXCR4 and CXCR7 expression were increased in AIDS-KS and classic KS versus angioma CBs (p<0.0001), as well as in nodular versus macular and papular lesions (p<0.0005). Similar results were obtained with Ki67 and VEGF expression (p<0.0001). There was no difference in LANA expression in AIDS-KS versus classic KS CBs, but LANA was significantly up-regulated in nodular lesions (p<0.0001). There were positive correlations between the trio expression, Ki67, LANA, VEGF and lesion severity (r=0.63-0.81, p<0.0001). The trio expression also correlated with the proliferation rate (r=0.50-0.69, p<0.002), latent HHV-8 level (r=0.56-0.74, p<0.001) and VEGF expression (r=0.41-0.77, p<0.02). No correlation was found with apoptosis level, patient age, CD4+ T cell count, lines of chemotherapy and KS disease duration.
Conclusions: This is the first in vivo study that highlights a concomitant up-regulation of the CXCL12/CXCR4-CXCR7 axis in KS. Such deregulation correlates with the disease severity. The CXCL12 signaling axis may be implicated in this virus-related cancer and could serve as a biomarker of KS severity.